Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genfit SA

www.genfit.com

Latest From Genfit SA

Genfit Thinks Intercept’s Lead In NASH Not As Wide As Perceived

Genfit believes elafibranor’s clean tolerability and safety profile may help narrow the gap between it and Intercept’s OCA, with safety questions delaying OCA’s entry to market. Part two of Scrip’s interview with Genfit’s CEO and COO.

Business Strategies Clinical Trials

Preparing For The NASH Market: A Conversation With Genfit Execs

As Genfit nears Phase III data for its NASH candidate elafibranor, it has promoted a new CEO and is working ahead on both an NDA filing and facing the commercial challenges of a new therapeutic space.

Liver & Hepatic Commercial

Intercept’s NASH NDA Positions OCA For May 2020 Approval, Then Launch

Intercept hopes to be first to market in NASH with an indication to treat fibrosis. It also is enrolling a study to show a benefit in NASH patients with cirrhosis.

Drug Approval Standards Clinical Trials

Intercept Could Face Tougher Road To NASH Approval In EU Than US

Recently filed NDA for obeticholic acid relies on US FDA's specified endpoints for treatment of fibrosis, but European standards are less clear cut, the company acknowledges.

Drug Approval Standards Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Hepatic (Liver)
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Genfit SA
  • Senior Management
  • Jean-Francois Mouney, Chmn. & CEO
    Nathalie Huitorel, EVP, CFO & Chief Administrative Officer
    Dean Hum, PhD, COO
    Carol L Addy, MD, CMO
  • Contact Info
  • Genfit SA
    Phone: (33) 3 20 16 40 00
    885 Ave. Eugene Avinee
    Parc Eurasante
    Loos, 59120
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register